The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 22, 2022

Filed:

Nov. 08, 2018
Applicants:

Paul B. Savage, Mapleton, UT (US);

Carl Genberg, Las Vegas, NV (US);

Ronald Bracken, Monroe, GA (US);

Inventors:

Paul B. Savage, Mapleton, UT (US);

Carl Genberg, Las Vegas, NV (US);

Ronald Bracken, Monroe, GA (US);

Assignee:

BRIGHAM YOUNG UNIVERSITY, Provo, UT (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61L 27/54 (2006.01); A61L 27/16 (2006.01); A61L 27/18 (2006.01); A61L 27/20 (2006.01); A61L 27/24 (2006.01); A61L 27/50 (2006.01); A61L 24/00 (2006.01); A61L 24/06 (2006.01); A61L 24/08 (2006.01); A61L 24/10 (2006.01); A61L 26/00 (2006.01); A61K 31/575 (2006.01); A61L 24/04 (2006.01); A61L 27/22 (2006.01); A61L 27/58 (2006.01);
U.S. Cl.
CPC ...
A61L 27/54 (2013.01); A61K 31/575 (2013.01); A61L 24/0015 (2013.01); A61L 24/046 (2013.01); A61L 24/06 (2013.01); A61L 24/08 (2013.01); A61L 24/102 (2013.01); A61L 26/0014 (2013.01); A61L 26/0019 (2013.01); A61L 26/0023 (2013.01); A61L 26/0033 (2013.01); A61L 26/0066 (2013.01); A61L 27/16 (2013.01); A61L 27/18 (2013.01); A61L 27/20 (2013.01); A61L 27/227 (2013.01); A61L 27/24 (2013.01); A61L 27/50 (2013.01); A61L 27/58 (2013.01); A61L 2300/216 (2013.01); A61L 2300/404 (2013.01); A61L 2300/41 (2013.01); A61L 2400/06 (2013.01); A61L 2430/34 (2013.01); A61L 2430/36 (2013.01);
Abstract

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.


Find Patent Forward Citations

Loading…